A

Arrowhead Pharmaceuticals

Develops RNAi-based gene-silencing therapies

Manager – Statistical Programming

Quantitative Biology & BiostatisticsConfirmed live in the last 24 hours
Full-timePasadena, CA, USA$145k - $160kIn-person

About the Job

Requirements

  • A Master’s degree in Biostatistics or Statistics is required.
  • Four years of relevant programming experience in pharmaceutical or biotechnology drug development is required.
  • Proficiency in statistical software including SAS, and familiarity with RStudio, are required.
  • Understanding and experience with aspects of the clinical development lifecycle, through regulatory submission and post-approval activities, are required.
  • Experience interacting with and overseeing programming services provided by contract research organization vendors is required.
  • Knowledge of cross-functional department functions and roles within a drug development company is required.

Responsibilities

  • Review analysis plans for appropriate methodologies.
  • Review clinical data as SDTM datasets.
  • Develop analysis databases using ADaM.
  • Program study analyses and review study results.
  • Conduct ad hoc and exploratory statistical analyses and support manuscript preparation.
  • Communicate project requirements for data cleanup and data capture to ensure key study variables are suitable for analysis.
  • Assist in identifying, developing, and implementing departmental standards, applications, processes, and training.
  • Assist in identifying consultants and selecting service providers, and oversee statistical and programming deliverables from contract research organizations or service providers.
  • Provide technical leadership and statistical programming input while collaborating with Clinical Development and Operations, Regulatory, Data Management, Medical Affairs, Program Management, and other functional teams.

Desired Qualifications

  • Understanding of regulatory guidelines related to dataset submissions using CDISC, including development of SDTM and ADaM specifications.

About the Company

Arrowhead Pharmaceuticals

Develops RNAi-based gene-silencing therapies

Arrowhead Pharmaceuticals develops medicines using RNA interference (RNAi) to silence disease-causing genes. The company’s approach uses a library of RNA chemistries and delivery methods to trigger RNAi, enabling rapid and durable reduction of target gene expression in cells. This gene-silencing strategy aims to treat severe genetic diseases such as cystic fibrosis and hepatitis B by lowering disease-related proteins. Arrowhead’s products are advanced through discovery and development partnerships, licensing deals, and potential commercialization of approved therapies. The company differentiates itself through a broad RNAi platform, proprietary delivery tech, and collaborations with larger pharma firms to advance its pipeline. Its goal is to provide new treatment options for conditions with limited or no effective therapies by translating gene silencing into medicines that can halt or reverse disease progression.

Company size
501-1,000
Company stage
IPO
Headquarters
Pasadena, CA
Founded
2004

Recently Posted Jobs

Explore more opportunities at Arrowhead Pharmaceuticals

See more jobs